Markets

Horizon Pharma (HZNP) Beats on Q3 Earnings and Revenues

Horizon PharmaHZNP , a biotechnology company, focuses areas like arthritis, inflammation and orphan diseases. This Dublin, Ireland based company has products like Vimovo, Duexis, Actimmune and Rayos.

The company has been quite active on the acquisition front over the past few quarters. Earlier this year, the company acquired Hyperion Therapeutics in a deal valued at about $1.1 billion. This deal will allow Horizon to strengthen its position in the orphan disease market with the addition of a couple of urea cycle disorder drugs to its portfolio.

Horizon Pharma has a disappointing earnings track record with the company recorded positive earnings surprises in one of the four trailing quarters with an average miss of 3.29%.

Currently, Horizon Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Horizon Pharma beat on earnings. Our consensus called for EPS of 41 cents, and the company reported EPS of 54 cents (these figures include stock-based compensation expense).

Revenue: Revenues were above expectations. Horizon Pharma posted revenues of $226.5 million, compared to our consensus estimate of $192 million.

Key Stats: The company's key products, Duexis, Rayos and Actimmune performed well during the quarter. The addition of Ravicti and Buphenyl is a huge boost to the company. The company raised its 2015 net sales guidance. The company now expects 2015 net sales to be around $750 to $760 million as compared to previous guidance of $660 million to $680 million.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

HORIZON PHARMA (HZNP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

HZNP

Other Topics

Earnings Investing Stocks

Latest Markets Videos